Obesity drugmakers are testing in kids as young as 6

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning. I was devastated to find out that we’ll no longer get sunsets after 7 p.m. until next spring. The need-to-know this morning Legend Biotech appointed Ingrid Zhang as its new CEO. Zhang is a former Novartis executive. She replaces Ying Huang, who resigned in July. With strong data, Vera to seek full approval of kidney drug Vera said this morning that its recently launched drug stabilized kidney function and reduced the risk of kidney-related death…

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Good morning. I was devastated to find out that we’ll no longer get sunsets after 7 p.m. until next spring.

The need-to-know this morning

Legend Biotech appointed Ingrid Zhang as its new CEO. Zhang is a former Novartis executive. She replaces Ying Huang, who resigned in July.

With strong data, Vera to seek full approval of kidney drug

Vera said this morning that its recently launched drug stabilized kidney function and reduced the risk of kidney-related death and other complications in a two-year trial of people with a chronic autoimmune kidney disease.

Continue to STAT+ to read the full story…